Analysts at several different firms weighed in on Dyax Corp. DYAX 53.69% Wednesday following the company’s announcement of data from a study on DX-2930 that handily beat market expectations.
The orphan drug, which was developed to treat a rare condition called hereditary angioedema (HAE), showed efficacy rates that vastly exceeded the numbers of major competitors in the space.
Shares of Dyax stock spiked as much as 55 percent on Wednesday morning. Here’s what some analysts had to say.
Bank Of America
Analysts praised the efficacy and safety results for DX-2930 and project a 2018 launch and a $530 million U.S. market for the drug by 2029. Bank of America raised its approval likelihood projections for the drug from 40 percent to 65 percent and raised penetration forecasts from 45 percent to 60 percent for the U.S. and from 45 percent to 50 percent for Europe.
Bank of America has a Buy rating on Dyax and raised its target for the stock from $16 to $30 following the results.
Leerink
Leerink analysts were also impressed by the results and adjusted projections for DX-2930 accordingly. Analysts are now forecasting a $1.3 billion gross market opportunity for the drug, up from a previous projection of only $700 million.
Leerink reiterated its Market Perform rating on Dyax, but raised its target for the stock from $16 to $25.
Analysts note that a potential takeout price for the company could be greater than $30 per share.
Oppenheimer
Oppenheimer analysts see the latest data on DX-2930 as a step toward the drug becoming the best-in-class prophylactic HAE treatment. Oppenheimer has an Outperform rating on Dyax and raised its target for the stock from $14 to $26.
Read this article and all my other articles for free on Benzinga by clicking here
Want to learn more about the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!
